Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.
Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Crit Care Med. 2021 Mar 1;49(3):503-516. doi: 10.1097/CCM.0000000000004817.
Respiratory failure, multiple organ failure, shortness of breath, recovery, and mortality have been identified as critically important core outcomes by more than 9300 patients, health professionals, and the public from 111 countries in the global coronavirus disease 2019 core outcome set initiative. The aim of this project was to establish the core outcome measures for these domains for trials in coronavirus disease 2019.
Three online consensus workshops were convened to establish outcome measures for the four core domains of respiratory failure, multiple organ failure, shortness of breath, and recovery.
International.
About 130 participants (patients, public, and health professionals) from 17 countries attended the three workshops.
None.
Respiratory failure, assessed by the need for respiratory support based on the World Health Organization Clinical Progression Scale, was considered pragmatic, objective, and with broad applicability to various clinical scenarios. The Sequential Organ Failure Assessment was recommended for multiple organ failure, because it was routinely used in trials and clinical care, well validated, and feasible. The Modified Medical Research Council measure for shortness of breath, with minor adaptations (recall period of 24 hr to capture daily fluctuations and inclusion of activities to ensure relevance and to capture the extreme severity of shortness of breath in people with coronavirus disease 2019), was regarded as fit for purpose for this indication. The recovery measure was developed de novo and defined as the absence of symptoms, resumption of usual daily activities, and return to the previous state of health prior to the illness, using a 5-point Likert scale, and was endorsed.
The coronavirus disease 2019 core outcome set recommended core outcome measures have content validity and are considered the most feasible and acceptable among existing measures. Implementation of the core outcome measures in trials in coronavirus disease 2019 will ensure consistency and relevance of the evidence to inform decision-making and care of patients with coronavirus disease 2019.
呼吸衰竭、多器官衰竭、呼吸急促、恢复和死亡率已被来自 111 个国家的 9300 多名患者、卫生专业人员和公众确定为至关重要的核心结局,这是全球 2019 年冠状病毒病核心结局集倡议的一部分。本项目的目的是为 2019 年冠状病毒病试验确定这四个核心领域的核心结局测量指标。
召开了三次在线共识研讨会,以确定呼吸衰竭、多器官衰竭、呼吸急促和恢复这四个核心领域的结局测量指标。
国际。
来自 17 个国家的约 130 名参与者(患者、公众和卫生专业人员)参加了三次研讨会。
无。
呼吸衰竭的评估依据世界卫生组织临床进展量表确定,需要呼吸支持,被认为具有务实性、客观性和广泛的适用性,适用于各种临床情况。推荐使用序贯器官衰竭评估来评估多器官衰竭,因为它在试验和临床护理中经常使用,经过良好验证,并且可行。对呼吸急促的改良医学研究理事会测量方法进行了适当调整(回忆期为 24 小时,以捕捉日常波动,并纳入活动,以确保相关性,并捕捉到患有 2019 年冠状病毒病患者呼吸急促的极端严重程度),被认为适用于该适应症。恢复测量是全新开发的,定义为无症状、恢复正常日常活动以及在患病前恢复到以前的健康状态,使用 5 点李克特量表进行评估,并得到认可。
2019 年冠状病毒病核心结局集推荐的核心结局测量具有内容有效性,并且被认为是现有测量方法中最可行和最可接受的。在 2019 年冠状病毒病试验中实施核心结局测量将确保证据的一致性和相关性,为 2019 年冠状病毒病患者的决策和护理提供信息。